News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalent Pharma Solutions Fined After Contact With Olanzapine Leads To Dermatitis


12/22/2010 8:31:51 AM

In-Pharma Technologists -- Catalent has been fined after contact with olanzapine led to employees developing dermatitis, an incident the company “deeply regrets”. The UK Health and Safety Executive (HSE) prosecuted Catalent after 10 employees at its Swindon plant developed allergic contact dermatitis, an irreversible skin condition. Catalent pleaded guilty and was ordered to pay a £50,000 ($77,000) fine and £50,000 in costs.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES